| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 22(2); 1990 > Article
Journal of the Korean Cancer Association 1990;22(2): 329-334.
진행된 위장관암에서 저용량의 경구용 Leucovorin 과 5-Fluorouracil 의 항암 효과
문한림, 김훈교, 이경식, 정진우, 이창돈, 김부성, 김동집, 최규호, 최경업
The Efficacy of 5-Fluorouracil and Low Dose Oral Leucovorin in Advanced GI Malignancies
Han Lim Moon, Hoon Kyo Kim, Kyung Shik Lee, Jin Woo Jung, Chang Don Lee, Boo Sung Kim, Dong Jip Kim, Kyu Ho Choi, Keung Eup Choi
Eighteen patients with GI malignancies (9 gastric, 3 colorectal, 3 pancreatic and 3 hepatobiliary cancer) were treated with oral leucovorin 15 mg administered every 6 hrs and IV 5-fluorouracil (5-FU) 500 mg/m started 1 hr after oral leucovorin for 5 consecutive days. The cycle was repeated every 3 weeks. When grade III or IV toxicities appeared, dose of 5-FU was reduced to 80% of initial one. Eight of 18 patients had previous experience of 5-FU containing chemotherapy. The results of study showed no objective responder of 16 evaluable patients. Eleven of 16 (69%) had stable disease and 5 (31%) Progressed initially. The overall survival of the study group was 9-65+ weeks (median: 36 wks). Survival of patients with stable disease and those with initial progression were 9+-65+ weeks (median: 41 weeks) and 9-21 (median: 13) weeks retrospectively (p<0.05). Toxicities were mild and tolerable. The most common and dose limiting toxicity was mucositis (83.3%). We concluded low dose oral leucovorin and 5-FU was tolerable, but not effective in GI malignancies.
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI